Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for anti-Pneumocystis jirovecii pneumonia (PcP) prophylaxis in kidney transplant recipients (KTR). Post-transplant management balances preventing PcP with managing TMP-SMX-related adverse effects. TMP-SMX dose reduction addres...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Infect Dis
Auteurs principaux: Prasad, G. V. Ramesh, Beckley, Jill, Mathur, Mohit, Gunasekaran, Madhushankar, Nash, Michelle M., Rapi, Lindita, Huang, Michael, Zaltzman, Jeffrey S.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6451305/
https://ncbi.nlm.nih.gov/pubmed/30953458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-019-3944-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires